非小细胞肺癌表皮生长因子受体-酪氨酸激酶抑制剂靶向治疗研究进展

Research Progress on EGFR-TKI Targeted Therapy for Non-Small Cell Lung Cancer

以表皮生长因子受体-酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitors,EGFR-TKIs)为代表的靶向治疗药物已显著改善非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的预后。随着肿瘤全程管理的推进,不断有研究展开探讨EGFR-TKIs在新辅助治疗、辅助治疗及晚期一线治疗(EGFR-TKIs单药治疗和联合化疗、抗血管生成治疗及免疫治疗)中的疗效。而EGFR-TKIs耐药成为靶向治疗无法避免的问题,导致耐药后的治疗陷入瓶颈。全文就EGFR-TKIs的临床应用、耐药机制及抗耐药治疗进行综述。

Targeted therapy represented by epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs)has significantly improved the prognosis of patients with non-small cell lung cancer(NSCLC).The efficacy of EGFR-TKIs(including EGFR-TKIs monotherapy and combined with chemotherapy,anti-angiogenesis therapy and immunotherapy)in neoadjuvant therapy,adjuvant therapy and first-line treatment for advanced-stage patients has been extensively explored.However,resis-tance to EGFR-TKIs in targeted therapy has become a challenge leading to the difficulty in post-resis-tance treatment.This paper reviews the clinical application,resistance mechanisms and anti-resis-tance treatments of EGFR-TKIs.